Ocugen Consolidates Below $10: A Good Buy Now?

The Ocugen stock has made many big moves at different times this year and although there was no major move in the stock on Wednesday, there is a new development that investors could follow. Ocugen (NASDAQ: OCGN) has made its name as a biotech company that is involved in developing treatments for rare conditions associated with blindness.


The potential positive trigger for the Ocugen stock could be the orphan drug status designation for one of its products from the regulatory authorities in Europe. On the other hand, the company has also turned into a COVID 19 play through its partnership with the India-based Bharat Biotech. By way of this partnership, Ocugen secured the rights to commercialize as well as develop the Bharat Biotech vaccine in the United States.

It has been one of the major reasons behind the considerable gains made by the Ocugen stock in recent days. Investors could consider keeping an eye on developments in the coming days.

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.

Michael Rowels has 964 posts and counting. See all posts by Michael Rowels